China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the China Drug Delivery Devices devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the Drug Delivery Devices in China

Scope

• The report provides drug delivery devices information broken down into detailed categories and segments in China.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

Reasons to buy

• Gain a strong understanding of the drug delivery devices market in China
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

• 1 Table Of Contents
• 1 Table Of Contents
  • 1.1 List of Tables
  • 1.2 List of Figures
• 2 Introduction
  • 2.1 What Is This Report About?
  • 2.2 Definitions
    • 2.2.1 Drug delivery devices
      • 2.2.1.1 Needle-free Injections
      • 2.2.1.2 Inhalation Systems
      • 2.2.1.3 Infusion Systems
• 3 Healthcare Sector Review
  • 3.1 Healthcare Expenditure
  • 3.2 Healthcare Infrastructure
    • 3.2.1 Healthcare Personnel Data
    • 3.2.2 Healthcare Facilities Data
  • 3.3 Healthcare Policy
• 4 Drug Delivery Devices in China
  • 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
  • 4.2 Drug Delivery Devices Overall Volume (2000-2012)
  • 4.3 Drug Delivery Devices Company Shares (2005-2006)
• 5 Inhalation Systems in China
  • 5.1 Inhalation Systems Overall Revenues (2000-2012)
    • 5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)
    • 5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)
  • 5.2 Inhalation Systems Overall Volume (2000-2012)
    • 5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)
    • 5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)
  • 5.3 Inhalation Systems Average Price (2000-2012)
    • 5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)
    • 5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)
  • 5.4 Inhalation Systems Distribution Share (2005-2006)
  • 5.5 Inhalation Systems Company Share (2005-2006)
• 6 Infusion Systems in China
  • 6.1 Infusion Systems Overall Revenues (2000-2012)
    • 6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)
    • 6.1.2 Syringe Pumps Overall Revenue (2000-2012)
    • 6.1.3 Infusion Pumps Overall Revenues (2000-2012)
  • 6.2 Infusion Systems Overall Volume (2000-2012)
    • 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
    • 6.2.2 Syringe Pumps Overall Volume (2000-2012)
    • 6.2.3 Infusion Pumps Overall Volume (2000-2012)
  • 6.3 Infusion Systems Average Price (2000-2012)
    • 6.3.1 Infusion Pumps Average Price (2000-2012)
    • 6.3.2 Syringe Pumps Average Price (2000-2012)
    • 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
  • 6.4 Infusion Systems Distribution Share (2005-2006)
  • 6.5 Infusion Systems Company Share (2005-2006)
• 7 AstraZeneca PLC Company Profile
  • 7.1 Company Overview
  • 7.2 Business Overview
    • 7.2.1 Products
    • 7.2.2 History
  • 7.3 Locations And Subsidiaries
  • 7.4 Financial Deals Landscape
    • 7.4.1 AstraZeneca Completes $6,900 Million Private Placement
    • 7.4.2 AstraZeneca Acquires MedImmune
    • 7.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
    • 7.4.4 AstraZeneca Acquires Arrow Therapeutics
    • 7.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
    • 7.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
    • 7.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
    • 7.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
    • 7.4.9 Schering Signs An Agreement With AstraZeneca
    • 7.4.10 AstraZeneca Signs An Agreement With Pozen
    • 7.4.11 AstraZeneca Signs An Agreement With Abbott
    • 7.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
    • 7.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
    • 7.4.14 AstraZeneca Acquires A Stake In Protherics
    • 7.4.15 AstraZeneca Signs An Agreement With Targacept
    • 7.4.16 AstraZeneca Signs An Agreement With AtheroGenics
    • 7.4.17 AstraZeneca UK Signs An Agreement With Protherics
    • 7.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
    • 7.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
    • 7.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
    • 7.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
    • 7.4.22 AstraZeneca Completes Private Placement Of $750 million
    • 7.4.23 AstraZeneca Prices EUR750 Million Private Placement
    • 7.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
  • 7.5 Recent Developments
    • 7.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
    • 7.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
    • 7.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
    • 7.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
    • 7.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
    • 7.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
    • 7.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
    • 7.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
    • 7.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
• 8 3M Company Profile
  • 8.1 Company Overview
  • 8.2 Business Overview
    • 8.2.1 Consumer and Office
      • 8.2.1.1 Overview
      • 8.2.1.2 Capital Expenditure
      • 8.2.1.3 Market View
      • 8.2.1.4 Key Strategies
    • 8.2.2 Display and Graphics
      • 8.2.2.1 Overview
      • 8.2.2.2 Financials
      • 8.2.2.3 Capital Expenditure
      • 8.2.2.4 Market View
      • 8.2.2.5 Key Strategies
    • 8.2.3 Electro and Communications
      • 8.2.3.1 Overview
      • 8.2.3.2 Financials
      • 8.2.3.3 Capital Expenditure
      • 8.2.3.4 Market View
      • 8.2.3.5 Key Strategies
    • 8.2.4 Health Care
      • 8.2.4.1 Overview
      • 8.2.4.2 Financials
      • 8.2.4.3 Capital Expenditure
      • 8.2.4.4 Market View
      • 8.2.4.5 Key Strategies
    • 8.2.5 Industrial and Transportation
      • 8.2.5.1 Overview
      • 8.2.5.2 Financials
      • 8.2.5.3 Capital Expenditure
      • 8.2.5.4 Market View
      • 8.2.5.5 Key Strategies
    • 8.2.6 Safety, Security and Protection Services
      • 8.2.6.1 Overview
      • 8.2.6.2 Financials
      • 8.2.6.3 Capital Expenditure
      • 8.2.6.4 Market View
      • 8.2.6.5 Key Strategies
    • 8.2.7 Products
  • 8.3 Value Chain Analysis
    • 8.3.1 Manufacturing
      • 8.3.1.1 In House Manufacturing
    • 8.3.2 Product Development
      • 8.3.2.1 Regulatory Approvals
      • 8.3.2.2 Clinical Trials
      • 8.3.2.3 Research and Development
    • 8.3.3 Sales and Marketing
      • 8.3.3.1 Partnerships and Alliances
      • 8.3.3.2 Licensing Agreements
      • 8.3.3.3 E-distribution
  • 8.4 SWOT Analysis
    • 8.4.1 3M Company Strengths
      • 8.4.1.1 Strong performance of Industrial and Transportation segment
      • 8.4.1.2 Focused research and development
      • 8.4.1.3 Decentralized operations
• 3M Company Weaknesses
  • 8.4.1.4 Increased operating costs in the U.S
    • 8.4.1.5 Personal care segment's poor performance
• 3M Company Opportunities
  • 8.4.1.6 Expanding global presence
    • 8.4.1.7 The liquid crystal display
    • 8.4.1.8 Enhancing brand portfolio
• 3M Company Threats
  • 8.4.1.9 Foreign currency fluctuations
    • 8.4.1.10 Increasing cost of raw materials
    • 8.4.1.11 Trend for private labels
  • 8.5 Revenue Analysis
    • 8.5.1 Revenue by Segment
    • 8.5.2 Revenue by Geography
  • 8.6 Financial and Operational Review
    • 8.6.1 Financial Statements
    • 8.6.2 Financial Ratios
  • 8.7 Locations And Subsidiaries
  • 8.8 Financial Deals Landscape
    • 8.8.1 3M Canada Acquires Les Entreprises Solumed
    • 8.8.2 3M Acquires Bondo
    • 8.8.3 3M Acquires Lingualcare
    • 8.8.4 3M Acquires Abzil Industria E Comercio
    • 8.8.5 3M Acquires Neo Plast
    • 8.8.6 3M Acquires Assets Of DMS Chile
    • 8.8.7 3M Acquires Business Of Innovative Paper Technologies
    • 8.8.8 3M Acquires Powell
    • 8.8.9 Gen-Probe Signs An Agreement With 3M Company
    • 8.8.10 3M Acquires Acolyte Biomedica
    • 8.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp
    • 8.8.12 3M Sells Its Pharmaceutical Business To Meda AB
    • 8.8.13 3M Acquires SoftMed Systems
    • 8.8.14 3M Sells its Pharmaceuticals Business to Graceway
    • 8.8.15 Gen-Probe Signs An Agreement With 3M
    • 8.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
    • 8.8.17 3M Acquires Biotrace International
    • 8.8.18 Ekahau Secures $16 Million In Additional Funding
    • 8.8.19 3M Acquires Brontes Technologies
    • 8.8.20 3M acquires Nylonge Corp
    • 8.8.21 3M Signs An Agreement With ClozeX Medical
    • 8.8.22 3M Acquires OMNII Oral Pharmaceuticals
    • 8.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway
    • 8.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB
    • 8.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
    • 8.8.26 3M Acquires Accuspray Application Technologies Inc
    • 8.8.27 3M to acquire Rochford Thompson Equipment
    • 8.8.28 3M To Acquire Aearo Technologies From Permira
    • 8.8.29 Permira To Sell Aearo Technologies To 3M
  • 8.9 Recent Developments
    • 8.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
    • 8.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
    • 8.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
    • 8.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
    • 8.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year
    • 8.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend
    • 8.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
    • 8.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend
    • 8.9.9 May 08, 2007: 3M Declares Quarterly Dividend
    • 8.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
• 9 Baxter International Company Profile
  • 9.1 Company Overview
  • 9.2 Business Overview
    • 9.2.1 BioScience
      • 9.2.1.1 Overview
      • 9.2.1.2 Financials
      • 9.2.1.3 Capital Expenditure
    • 9.2.2 Medication Delivery
      • 9.2.2.1 Overview
      • 9.2.2.2 Financials
      • 9.2.2.3 Capital Expenditure
    • 9.2.3 Renal
      • 9.2.3.1 Overview
      • 9.2.3.2 Financials
      • 9.2.3.3 Capital Expenditure
    • 9.2.4 Products
    • 9.2.5 History
  • 9.3 Value Chain Analysis
    • 9.3.1 Manufacturing
      • 9.3.1.1 In House Manufacturing
    • 9.3.2 Product Development
      • 9.3.2.1 Regulatory Approvals
      • 9.3.2.2 Clinical Trials
      • 9.3.2.3 Research and Development
    • 9.3.3 Sales and Marketing
      • 9.3.3.1 Partnerships and Alliances
  • 9.4 SWOT Analysis
    • 9.4.1 Baxter International Inc. Strengths
      • 9.4.1.1 Diversified geographic presence
      • 9.4.1.2 Sturdy research and development activities
      • 9.4.1.3 Strong financial performance
    • 9.4.2 Baxter International Inc. Weaknesses
      • 9.4.2.1 High levels of inventory
      • 9.4.2.2 Decline in revenues of medication delivery
      • 9.4.2.3 Reduced capital expenditure
    • 9.4.3 Baxter International Inc. Opportunities
      • 9.4.3.1 Co-developing alliances
      • 9.4.3.2 Increasing End Stage Renal Disease patients
      • 9.4.3.3 FDA approval
    • 9.4.4 Baxter International Inc. Threats
      • 9.4.4.1 Legal proceedings
      • 9.4.4.2 Patent litigation
      • 9.4.4.3 Stringent regulations
  • 9.5 Revenue Analysis
    • 9.5.1 Revenue by Segment
    • 9.5.2 Revenue by Geography
  • 9.6 Financial and Operational Review
    • 9.6.1 Financial Statements
    • 9.6.2 Financial Ratios
  • 9.7 Locations And Subsidiaries
  • 9.8 Financial Deals Landscape
    • 9.8.1 Baiyunshan And Baxter Form A Joint Venture In China
    • 9.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
    • 9.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
    • 9.8.4 B. Braun Acquires Renal Therapy Business Of Baxter
    • 9.8.5 Innovata signs a license agreement with Baxter International
    • 9.8.6 Kuros Biosurgery Signs An Agreement With Baxter International
    • 9.8.7 Gambro Signs An Agreement With Baxter
    • 9.8.8 Baxter Healthcare And Gambro Enter Into An Agreement
    • 9.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
    • 9.8.10 Baxter International And Kaketsuken Enter Into Agreement
    • 9.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
  • 9.9 Recent Developments
    • 9.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
    • 9.9.2 Dec 18, 2007: Baxter Elects CFO
    • 9.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
    • 9.9.4 Aug 01, 2007: Baxter Elects New Board Director
    • 9.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
    • 9.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
    • 9.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
    • 9.9.8 Nov 28, 2006: Baxter Announces Annual Dividend
    • 9.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
  • 9.10 Baxter International Inc. Pipeline Products
    • 9.10.1 Next-Generation Home Hemodialysis Machine
      • 9.10.1.1 Product Overview
      • 9.10.1.2 Product Description
      • 9.10.1.3 Product Status
      • 9.10.1.4 Product Milestone
• 10 GlaxoSmithKline plc Company Profile
  • 10.1 Company Overview
  • 10.2 Business Overview
    • 10.2.1 Products
    • 10.2.2 History
  • 10.3 Locations And Subsidiaries
  • 10.4 Financial Deals Landscape
    • 10.4.1 GlaxoSmithKline Acquires CNS
    • 10.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
    • 10.4.3 CNS To Merge With GlaxoSmithKline
  • 10.5 Recent Developments
    • 10.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
    • 10.5.2 Feb 07, 2008: Full-year results announcement 2007
    • 10.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
    • 10.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
    • 10.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
• 11 Novartis AG Company Profile
  • 11.1 Company Overview
  • 11.2 Business Overview
    • 11.2.1 Major Products and Services
  • 11.3 Locations And Subsidiaries
  • 11.4 Financial Deals Landscape
    • 11.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis
    • 11.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle
    • 11.4.3 Novartis to sell Medical Nutrition business unit to Nestl
    • 11.4.4 Nestl to Acquire Novartis Medical Nutrition
    • 11.4.5 Novartis to sell its division Gerber Products Company to Nestle
• 12 Regulation System
  • 12.1 Medical Equipment Approval Process
    • 12.1.1 Classification
    • 12.1.2 Registration and Conformity assessment
    • 12.1.3 China Compulsory Certificate (CCC Mark)
    • 12.1.4 Labeling and Packaging
    • 12.1.5 Registration Fee
    • 12.1.6 Registration Period
  • 12.2 Post Market Surveillance (PMS)
• 13 Pricing and Reimbursement
• 14 Distribution Structure
• 15 APPENDIX
  • 15.1 Global Markets Direct Research Methodology
  • 15.2 Coverage
  • 15.3 Secondary Research
  • 15.4 Primary Research
  • 15.5 Models
  • 15.6 Forecasts
  • 15.7 Expert Panels
  • 15.8 Currency Conversion
  • 15.9 Contact Us
  • 15.10 Disclaimer
• List of Tables
  • Table 1: Doctors by Specialty in China, 2003-2007
  • Table 2: Hospital Wards by Specialty in China, 2003 - 2007
  • Table 3: Healthcare Institutions in China, 2000-2004
  • Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2004
  • Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2004
  • Table 6: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012
  • Table 7: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 8: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 9: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012
  • Table 10: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007
  • Table 11: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012
  • Table 12: Drug Delivery Devices, China, Category Volume (Units), 2000-2012
  • Table 13: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007
  • Table 14: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012
  • Table 15: Drug Delivery Devices, China, Company Share by Revenue ($ mn), 2005-2006
  • Table 16: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 17: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 18: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
  • Table 19: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
  • Table 20: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 21: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 22: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 23: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 24: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007
  • Table 25: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 26: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
  • Table 27: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 28: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
  • Table 29: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 30: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007
  • Table 31: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
  • Table 32: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007
  • Table 33: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
  • Table 34: Inhalation Systems, China, Distribution Share by Revenue ($ mn), 2005-2006
  • Table 35: Inhalation Systems, China, Company Share by Revenue ($ mn), 2005-2006
  • Table 36: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 37: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 38: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
  • Table 39: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
  • Table 40: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 41: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 42: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 43: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 44: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Table 45: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Table 46: Infusion Systems, China, Overall Volume (Units), Historic, 2000-2007
  • Table 47: Infusion Systems, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 48: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007
  • Table 49: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 50: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007
  • Table 51: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 52: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007
  • Table 53: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012
  • Table 54: Infusion Pumps, China, Average Price ($), Historic, 2000-2007
  • Table 55: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012
  • Table 56: Syringe Pumps, China, Average Price ($), Historic, 2000-2007
  • Table 57: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012
  • Table 58: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007
  • Table 59: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012
  • Table 60: Infusion Systems, China, Distribution Share by Revenue ($ mn), 2005-2006
  • Table 61: Infusion Systems, China, Company Share by Revenue ($ mn), 2005-2006
  • Table 62: AstraZeneca PLC, Subsidiaries
  • Table 63: AstraZeneca PLC, Subsidiaries(Contd..)
  • Table 64: 3M Company, SWOT Analysis, 2006
  • Table 65: 3M Company, Revenue by Segment, USD Million, 2003-2007
  • Table 66: 3M Company, Revenue by Geography, USD Million, 2003-2007
  • Table 67: 3M Company, Financial Statements, USD Million, 2003-2007
  • Table 68: 3M Company, Financial Ratios, USD Million, 2003-2007
  • Table 69: 3M Company, Subsidiaries
  • Table 70: Baxter International Inc., SWOT Analysis, 2006
  • Table 71: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007
  • Table 72: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007
  • Table 73: Baxter International Inc., Financial Statements, USD Million, 2003-2007
  • Table 74: Baxter International Inc., Financial Ratios, USD Million, 2003-2007
  • Table 75: Baxter International Inc., Other Locations
  • Table 76: Baxter International Inc., Subsidiaries
  • Table 77: GlaxoSmithKline plc, Subsidiaries
  • Table 78: GlaxoSmithKline plc, Subsidiaries(Contd..)
  • Table 79: Novartis Medical Nutrition, Other Locations
  • Table 80: Novartis Medical Nutrition, Other Locations(Contd..)
  • Table 81: Currency Conversion from USD to Local Currency at 2007 Constant Rate
• List of Figures
  • Figure 1: Total Healthcare Expenditure in China, 2000 - 2005
  • Figure 2: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012
  • Figure 3: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 4: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 5: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012
  • Figure 6: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007
  • Figure 7: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012
  • Figure 8: Drug Delivery Devices, China, Category Volume (Units), 2000-2012
  • Figure 9: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007
  • Figure 10: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012
  • Figure 11: Drug Delivery Devices, China, Company Share (%), 2006
  • Figure 12: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 13: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 14: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
  • Figure 15: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
  • Figure 16: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 17: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 18: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 19: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 20: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007
  • Figure 21: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012
  • Figure 22: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
  • Figure 23: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
  • Figure 24: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
  • Figure 25: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
  • Figure 26: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007
  • Figure 27: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
  • Figure 28: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007
  • Figure 29: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
  • Figure 30: Inhalation Systems, China, Distribution Share (%), 2006
  • Figure 31: Inhalation Systems, China, Company Share (%), 2006
  • Figure 32: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 33: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 34: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
  • Figure 35: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
  • Figure 36: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 37: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 38: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 39: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 40: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
  • Figure 41: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
  • Figure 42: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007
  • Figure 43: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012
  • Figure 44: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007
  • Figure 45: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012
  • Figure 46: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007
  • Figure 47: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012
  • Figure 48: Infusion Pumps, China, Average Price ($), Historic, 2000-2007
  • Figure 49: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012
  • Figure 50: Syringe Pumps, China, Average Price ($), Historic, 2000-2007
  • Figure 51: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012
  • Figure 52: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007
  • Figure 53: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012
  • Figure 54: Infusion Systems, China, Distribution Share (%), 2006
  • Figure 55: Infusion Systems, China, Company Share (%), 2006
  • Figure 56: 3M Company, Value Chain Analysis
  • Figure 57: Baxter International Inc., Value Chain Analysis
  • Figure 58: Medical Equipment Registration Process in China, 2007
  • Figure 59: CCC Mark Certification Process in China, 2007
  • Figure 60: Global Markets Direct Methodology